Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 10/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CCL2 | P13500 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900879 | 0.82 | IDO1 (0.43) | IDO1AGXTF2MAOB | |
| SCHEMBL8698257 | 0.82 | BCHE (0.42) | IDO1AGXTMAOBCYP4F2CYP4A11 | |
| SCHEMBL15778630 | 0.81 | IDO1 (0.60) | IDO1AGXTMAOB | |
| SCHEMBL8699737 | 0.81 | GGPS1 (0.39) | IDO1AGXTF2 | |
| SCHEMBL8715771 | 0.81 | IDO1 (0.39) | IDO1AGXTF2MAOBCYP4F2 | |
| SCHEMBL8701740 | 0.80 | IDO1 (0.38) | IDO1AGXTF2MAOBCYP4F2 | |
| SCHEMBL8699363 | 0.79 | TSHR (0.38) | IDO1AGXTF2CYP4F2CYP4A11 | |
| SCHEMBL8703174 | 0.79 | MAPK1 (0.41) | — | |
| SCHEMBL28079112 | 0.79 | IDO1 (0.40) | IDO1AGXTF2MAOB | |
| SCHEMBL31385483 | 0.79 | MAOB (0.42) | MAOBCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998008838-A1 | SUBSTITUTED AMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-03-05 | — | — | WO | disclosed |